Physician profile
John W Edwards
NPI 1417905639
$3,909.70
in general payments reported to CMS, 2019-2025
36 companies · $665 in 2025
The $665 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $335 · 2021: $890 · 2022: $621 · 2023: $562 · 2024: $426 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,653.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $420.61 | 2022-2025 | Urolift, Barrigel |
| Bayer Healthcare Pharmaceuticals INC. | $364.63 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $279.64 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $275.82 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $273.98 | 2021-2025 | Prolaris |
| Pfizer INC. | $257.34 | 2019-2024 | |
| Urogen Pharma, INC. | $218.91 | 2020-2025 | Jelmyto |
| Acerus Pharmaceuticals Corporation | $192.47 | 2020-2022 | |
| Myovant Sciences INC. | $168.79 | 2021-2022 | |
| Janssen Biotech, INC. | $152.22 | 2019-2021 | |
| Myovant Sciences Gmbh | $125.00 | 2021 | |
| Boston Scientific Corporation | $124.02 | 2019-2023 | Spaceoar Vue System - 10ml |
| Progenics Pharmaceuticals, INC. | $103.57 | 2021-2025 | Pylarify |
| Abbvie INC. | $94.63 | 2021-2022 | |
| Neotract INC. | $91.77 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $90.61 | 2021-2023 | |
| Travere Therapeutics, INC. | $63.11 | 2020-2021 | |
| Urovant Sciences INC | $62.17 | 2022 | |
| Accord Healthcare, INC. | $58.31 | 2023-2024 | |
| Endo Pharmaceuticals INC. | $51.19 | 2019-2020 | |
| Bluewind Medical | $48.39 | 2024 | Revi |
| 180 Medical, INC. | $43.75 | 2020-2021 | |
| Allergan, INC. | $43.25 | 2020-2021 | |
| C. R. Bard, INC. & Subsidiaries | $42.58 | 2022 | |
| Ferring Pharmaceuticals INC. | $37.00 | 2025 | Adstiladrin |
| Tolmar, INC. | $31.71 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $23.83 | 2019 | |
| Bard Peripheral Vascular, INC. | $21.13 | 2019 | |
| Verity Pharmaceuticals INC. | $21.08 | 2025 | Trelstar |
| Olympus America INC. | $20.55 | 2022 | |
| Hollister Incorporated | $19.65 | 2019 | |
| Procept Biorobotics Corporation | $19.54 | 2023 | Aquabeam Robotic System |
| Dendreon Pharmaceuticals LLC | $18.33 | 2025 | Provenge |
| Endo USA, INC. | $17.18 | 2025 | Xiaflex |
| Novo Nordisk INC | $16.77 | 2024 | |
| Lumenis, INC | $16.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.